TW200722091A - Combinations, methods and compositions for treating cancer - Google Patents
Combinations, methods and compositions for treating cancerInfo
- Publication number
- TW200722091A TW200722091A TW095113103A TW95113103A TW200722091A TW 200722091 A TW200722091 A TW 200722091A TW 095113103 A TW095113103 A TW 095113103A TW 95113103 A TW95113103 A TW 95113103A TW 200722091 A TW200722091 A TW 200722091A
- Authority
- TW
- Taiwan
- Prior art keywords
- methods
- compositions
- combinations
- treating cancer
- bcr
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 210000000130 stem cell Anatomy 0.000 abstract 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- OLCWFLWEHWLBTO-HSZRJFAPSA-N BMS-214662 Chemical compound C=1C=CSC=1S(=O)(=O)N([C@@H](C1)CC=2C=CC=CC=2)CC2=CC(C#N)=CC=C2N1CC1=CN=CN1 OLCWFLWEHWLBTO-HSZRJFAPSA-N 0.000 abstract 1
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 abstract 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67074405P | 2005-04-13 | 2005-04-13 | |
| US74843305P | 2005-12-08 | 2005-12-08 | |
| US11/402,502 US20060235006A1 (en) | 2005-04-13 | 2006-04-12 | Combinations, methods and compositions for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200722091A true TW200722091A (en) | 2007-06-16 |
Family
ID=37109315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095113103A TW200722091A (en) | 2005-04-13 | 2006-04-13 | Combinations, methods and compositions for treating cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20060235006A1 (https=) |
| EP (1) | EP1868435A4 (https=) |
| JP (1) | JP2008536853A (https=) |
| KR (1) | KR20080004495A (https=) |
| AU (1) | AU2006236812A1 (https=) |
| BR (1) | BRPI0608176A2 (https=) |
| CA (1) | CA2604581A1 (https=) |
| EA (1) | EA200702238A1 (https=) |
| MX (1) | MX2007012537A (https=) |
| NO (1) | NO20075087L (https=) |
| TW (1) | TW200722091A (https=) |
| WO (1) | WO2006113304A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1169038B9 (en) * | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| WO2006135790A1 (en) * | 2005-06-09 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mutant kit protein |
| EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| WO2007059143A2 (en) * | 2005-11-15 | 2007-05-24 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof |
| CA2644143C (en) * | 2006-04-05 | 2013-10-01 | Novartis Ag | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
| KR101292508B1 (ko) * | 2006-04-07 | 2013-08-01 | 노파르티스 아게 | 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도 |
| WO2008064004A2 (en) * | 2006-11-16 | 2008-05-29 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml) |
| US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
| WO2008089135A2 (en) * | 2007-01-12 | 2008-07-24 | University Of South Florida | Identification of biomarkers predictive of dasatinib effects in cancer cells |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| EP2222166B9 (en) * | 2007-12-10 | 2012-11-07 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
| BRPI0914790A2 (pt) | 2008-06-17 | 2015-10-20 | Wyeth Llc | uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| US8669273B2 (en) * | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| EP2370175A2 (en) * | 2008-12-16 | 2011-10-05 | Bristol-Myers Squibb Company | Methods of inhibiting quiescent tumor proliferation |
| PT2769737T (pt) * | 2009-07-20 | 2017-06-29 | Bristol Myers Squibb Co | Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas |
| EP2470212A4 (en) * | 2009-10-01 | 2013-12-04 | Csl Ltd | METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011029A (en) * | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| EP1169038B9 (en) * | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| CA2444867C (en) * | 2001-05-16 | 2010-08-17 | Novartis Ag | Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent |
| WO2004015130A2 (en) * | 2002-08-07 | 2004-02-19 | Exelixis | Modulators of rabggt and methods of use thereof |
| US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| PE20051096A1 (es) * | 2004-02-04 | 2006-01-23 | Novartis Ag | Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida |
| US7491725B2 (en) * | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
-
2006
- 2006-04-12 US US11/402,502 patent/US20060235006A1/en not_active Abandoned
- 2006-04-13 AU AU2006236812A patent/AU2006236812A1/en not_active Abandoned
- 2006-04-13 CA CA002604581A patent/CA2604581A1/en not_active Abandoned
- 2006-04-13 BR BRPI0608176-2A patent/BRPI0608176A2/pt not_active IP Right Cessation
- 2006-04-13 MX MX2007012537A patent/MX2007012537A/es not_active Application Discontinuation
- 2006-04-13 EP EP06749971A patent/EP1868435A4/en not_active Withdrawn
- 2006-04-13 KR KR1020077023422A patent/KR20080004495A/ko not_active Withdrawn
- 2006-04-13 EA EA200702238A patent/EA200702238A1/ru unknown
- 2006-04-13 TW TW095113103A patent/TW200722091A/zh unknown
- 2006-04-13 WO PCT/US2006/013773 patent/WO2006113304A2/en not_active Ceased
- 2006-04-13 JP JP2008506668A patent/JP2008536853A/ja not_active Withdrawn
-
2007
- 2007-10-09 NO NO20075087A patent/NO20075087L/no not_active Application Discontinuation
-
2008
- 2008-10-23 US US12/256,771 patent/US20090054415A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0608176A2 (pt) | 2009-11-17 |
| WO2006113304A2 (en) | 2006-10-26 |
| NO20075087L (no) | 2008-01-09 |
| MX2007012537A (es) | 2007-12-10 |
| EP1868435A4 (en) | 2009-04-01 |
| US20060235006A1 (en) | 2006-10-19 |
| CA2604581A1 (en) | 2006-10-26 |
| JP2008536853A (ja) | 2008-09-11 |
| KR20080004495A (ko) | 2008-01-09 |
| EP1868435A2 (en) | 2007-12-26 |
| WO2006113304A3 (en) | 2007-08-02 |
| EA200702238A1 (ru) | 2008-04-28 |
| US20090054415A1 (en) | 2009-02-26 |
| AU2006236812A1 (en) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075087L (no) | Kombinasjoner, metoder og sammensetninger for behandling av cancer | |
| NO20075154L (no) | Formuleringer av en src/abl-inhibitor | |
| AP1545A (en) | Hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione. | |
| ATE481093T1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| AR104566A2 (es) | Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo | |
| WO2007125310A3 (en) | Pharmaceutical combinations of pk inhibitors and other active agents | |
| NO20084923L (no) | N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer | |
| EA200800727A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
| UA96126C2 (ru) | Соединение для ингибирования активности rho киназы, фармацевтическая композиция, которая содержит такое соединение, и способ ингибирования активности rho киназы | |
| NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
| EA201000300A1 (ru) | Способ синтеза соединений, пригодных для лечения гепатита с | |
| EA200702568A1 (ru) | Гетеробициклические ингибиторы металлопротеазы и их применение | |
| TW200714589A (en) | Phenylacetamides suitable as protein kinase inhibitors | |
| NO20092412L (no) | Hydantoinderivater anvendes som MMP-inhibitorer | |
| PE20061394A1 (es) | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas | |
| MX2009012525A (es) | Pirazol-pirrolidinas como inhibidores de gamma secretasa. | |
| WO2006004937A3 (en) | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders | |
| TW200800940A (en) | New primary amines | |
| MX2009003974A (es) | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion. | |
| PE20091617A1 (es) | Tiazolil-dihidro-indazoles | |
| ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors | |
| WO2007068728A3 (en) | N-substituted pyrrolopyridinones active as kinase inhibitors | |
| AP1715A (en) | The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione | |
| BRPI0614481A2 (pt) | composto, composição farmecêutica, uso do composto, e, método de tratamento de distúrbios mediados por mglur5 | |
| AR053226A1 (es) | Combinaciones metodos y composiciones para tratar el cancer |